Virtual Summit June 1: Deep Dive Into Prescription Digital Therapeutics Register Close

Partnership Forums

Live and interactive, AMCP Partnership Forums bring together key decision-makers in managed care, integrated care networks, the pharmaceutical industry, and other vital sectors to discuss and collaborate on strategies to drive efficiency and improve patient outcomes. Designed to address current market challenges and opportunities, AMCP Partnership Forums also: 

  • Take a proactive, collaborative approach to solving critical issues and challenges. 
  • Gain consensus on challenges or opportunities to remove barriers to improve patient care and optimize value for all stakeholders. 
  • Represent opportunities for payers, manufacturers, patients, and other stakeholders to work together on common goals and interests and create actionable results. 
  • Experience high visibility among industry stakeholders and policymakers. 

Upcoming Partnership Forums:

Patient Input and Payer Decision-Making 

December 6-7, 2023 | Old Town Alexandria, VA

There is a growing consensus for health care to be “patient-centered” taking patient preferences, needs, and values into consideration for clinical decision-making. The Food and Drug Administration piloted and invested in the patient-focused drug development program and the Centers for Medicare and Medicaid Services prioritized patient-reported measures and other patient-generated data for use in the quality measures. For population health decisions and managed care pharmacy this includes supplementing existing evidence with scientifically generated patient-information and prioritizing outcomes that are meaningful to patients in value and coverage determinations. 

Outside of the US, health technology assessment groups engage patients when assessing value and making reimbursement decisions in various ways. However, within the US, there is lack of clarity for both managed care pharmacy and patient advocacy organizations on key questions such as: Whose input be sought? What input should be considered? And does information from patients alter or improve the decisions or decision certainty?  

Past Partnership Forums:

Watch highlights from our most recent Partnership Forum. 

View more past Partnership Forums.

Ongoing:

ADVISORY GROUP — Addressing Barriers to Value-Based Payment Models in Integrated Delivery Networks

Collaborate with a group of key stakeholders to address how existing laws are impacting integrated delivery networks (IDNs) and pharmaceutical partnerships. Legal and regulatory requirements (e.g., the Anti-Kickback Statute and Medicaid best price rule) can limit the use of certain strategies that could potentially improve care coordination and patient outcomes. Successful implementation of value-based agreements in IDNs requires a range of complex capabilities. The workgroup will provide examples of real-world challenges and possible solutions that will inform and support efforts for legislative change.

ADVISORY GROUP — Substance Use Disorder: A Focus on Prescription Drug Use 

Despite efforts to decrease the use of opioids, challenges remain. AMCP created multiple advisory groups beginning in 2015 recognizing the widespread and devastating nature of the opioid crisis.  Over time, these groups addressed access to medications for treatment of substance use disorders and  developed a viewpoint document on the importance of co-prescribing naloxone. The purpose of this group is to continue the work of the previous groups and focus on collecting and disseminating guidelines for managed care pharmacists regarding integrated care models and benefit designs that effectively address  substance use disorder. 

ADVISORY GROUP — Health Disparities

Now more than ever, there is an increased focus on health disparities that occur across a multitude of factors, including socioeconomic status, ethnicity, and race. As part of AMCP's strategic priority on addressing health disparities and commitment to transition from awareness to action, AMCP is committed to leveraging managed care pharmacy to address disparities in benefit design, medication use and outcomes in underserved populations. This advisory group will build upon the recommendations put forth during AMCP's 2021 Partnership Forum and will provide guidance as AMCP works to create awareness on the role of managed care professionals in this area, identify partners, and develop tools and resources to aid managed care pharmacy transition from awareness to action.

ADVISORY GROUP — Digital Therapeutics 

The role of digital therapeutics in preventing, managing, and treating medical conditions continues to evolve, offering the potential for therapeutic benefit. AMCP is committed to leveraging managed care pharmacy to continue to evolve the use of digital therapeutics to improve patient care and outcomes. This group will build upon the recommendations put forth during the pervious AMCP Partnership Forums and provide guidance to AMCP in its efforts to establish the leadership role of managed care pharmacy professionals in this area, identify potential partners, and assist in the creation and dissemination of tools and resources to enhance the coverage and utilization of digital therapeutics.